Original language | English (US) |
---|---|
Pages (from-to) | 583-585 |
Number of pages | 3 |
Journal | JAMA ophthalmology |
Volume | 139 |
Issue number | 5 |
DOIs | |
State | Published - May 2021 |
ASJC Scopus subject areas
- Ophthalmology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: JAMA ophthalmology, Vol. 139, No. 5, 05.2021, p. 583-585.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - MOG-IgG among participants in the pediatric optic neuritis prospective outcomes study
AU - Pediatric Eye Disease Investigator Group (PEDIG)
AU - Chen, John J.
AU - Pineles, Stacy L.
AU - Repka, Michael X.
AU - Pittock, Sean J.
AU - Henderson, Robert J.
AU - Liu, Grant T.
N1 - Funding Information: Conflict of Interest Disclosures: Dr Pittock reports grants from Grifols and the Autoimmune Encephalitis Alliance; honoraria and travel expenses from MedImmune, Inc and Alexion Pharmaceuticals, Inc; consulting fees from Astellas; personal fees from Genentech Sage Therapeutics, and Prime Therapeutics, UCB, Inc, and Hoffman/LaRoche AG; and consulting compensation from Euroimmun outside the submitted work; and has patents 8,889,102 for neuromyelitis optica autoantibodies as a marker for neoplasia and 9,891,219B2 for methods for treating neuromyelitis optica by administration of eculizumab to an individual that is aquaporin-4-IgG autoantibody positive; and pending patents for GFAP-IgG, Septin-5-IgG, MAP1B-IgG, Kelch-like protein 11, and PDE10A. No other disclosures were reported. Funding/Support: This research was supported by grants EY011751, EY018810, and EY023198 from the National Eye Institute. Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
PY - 2021/5
Y1 - 2021/5
UR - http://www.scopus.com/inward/record.url?scp=85103354023&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103354023&partnerID=8YFLogxK
U2 - 10.1001/jamaophthalmol.2021.0349
DO - 10.1001/jamaophthalmol.2021.0349
M3 - Letter
C2 - 33764379
AN - SCOPUS:85103354023
SN - 2168-6165
VL - 139
SP - 583
EP - 585
JO - JAMA ophthalmology
JF - JAMA ophthalmology
IS - 5
ER -